Jay Venkatesan, MD, MBA, President and CEO
Prior to Angion, Dr. Venkatesan served as President and Director of Alpine Immune Sciences (ALPN), which he co-founded as a Managing Partner of Alpine BioVentures. Previously, Dr. Venkatesan was the founder and portfolio manager of Ayer Capital, a global healthcare fund. Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed healthcare investments. He was also a consultant at McKinsey & Co. and a venture investor with Patricof & Co. Ventures (now Apax Partners). He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.
Itzhak Goldberg, MD., FACR, Executive Chairman, Board Chairman, and CSO
Dr. Goldberg was formerly a faculty member at Harvard Medical School, Boston, MA, Radiation Oncologist-in-Chief for the North Shore-LIJ (Northwell) Health System, , NY, and Professor at the Albert Einstein College of Medicine, Bronx, NY. Dr. Goldberg has made seminal contributions in the field of Tyrosine Kinase Receptors and Hepatocyte Growth Factor research and has been the driving force within Angion since he started the company. Under Dr. Goldberg’s leadership Angion received continuous non-dilutive NIH, DOD and NSF grants and successfully raised Series A/B funding.
John F. Neylan, M.D. Senior Vice President and Chief Medical Officer
Prior to Angion, Dr. Neylan served as Chief Medical Officer of Keryx, a biopharmaceutical company focused on nephrology. Previously, Dr. Neylan served as Senior Vice President, Clinical Development, at Genzyme Corporation, focusing on specialty metabolic diseases. From 2000-2008, Dr. Neylan served as Vice President, Research and Development for Wyeth Research, overseeing the clinical development of transplantation therapeutics and providing medical affairs support to the transplant franchise.
Prior to joining industry, Dr. Neylan held prestigious positions in academia, including Professor of Medicine at Emory University and Assistant Professor of Medicine at University of California, Davis, serving at both institutions as Medical Director of the respective Renal Transplant Programs, with oversight of the clinical research programs. Dr. Neylan received his BS from Duke University and his MD from Rush Medical School in Chicago. He completed his Internal Medicine residency at Vanderbilt University and fellowships in Nephrology and in Transplantation and Immunogenetics at Brigham and Women’s Hospital, Harvard University. Dr. Neylan has a proven track record for successful INDs, NDA/BLAs, and MAAs involving NCEs, polymers, biologics and RNA-based therapeutics and has authored more than 70 scientific manuscripts and book chapters. He is Past-President of the American Society of Transplantation and past Board Member of the National Kidney Foundation, and a past Industry Representative on the FDA Cardiovascular and Renal Drugs Advisory Committee.
Cynthia Smith, Senior Advisor
Cynthia is an advisor to Angion in the areas of corporate strategy, operations, and commercialization. Prior to Angion, Cynthia was Chief Commercial Officer of ZS Pharma. As an early member of the executive team, she led the company’s transition from R&D to product commercialization and played a key role in its successful IPO and acquisition by AstraZeneca.
Prior to joining ZS Pharma, Cynthia was VP, Market Access & Commercial Development at Affymax, where she launched the company’s first therapeutic in the nephrology market. Prior to joining Affymax, Cynthia held leadership roles at Merck in the areas of corporate strategy, market access, and public affairs. Before joining the pharmaceutical industry, Cynthia served on the health care policy team of The White House Office of Management and Budget (OMB).
Cynthia is on the board of directors of Dicerna Pharmaceuticals and Akebia Therapeutics. She earned an MBA from the Wharton School at the University of Pennsylvania, an MS in Public Policy from the Eagleton Institute at Rutgers University, and a BA from the University of North Carolina at Chapel Hill.
Prakash Narayan, Ph.D., Vice President - Preclinical Research
Dr. Narayan is an expert in models of acute organ injury and fibrosis and is the recipient of multiple NIH, DoD and NSF translational research awards. He is an expert panelist for the European Society of Translational Medicine and a member of the Baltimore PKD Organization. Dr. Narayan received his doctorate from Ohio State University and conducted postdoctoral research at University of Wisconsin-Madison.
Elisha Y. Goldberg, MBA, Director of Business Development
Mr. Goldberg leads business developments efforts for Angion Biomedica. Primary responsibilities include capital raising, strategic partnerships, and licensing agreements. Mr. Goldberg previously founded Broadfire Technologies, a thin client architecture company run out of MIT’s Lab for Computer Science (LCS) under Dr. Michael Dertouzos. He has also worked in equities and investment banking for multiple financial institutions, including Goldman Sachs, in the United States and abroad. Mr. Goldberg received his MBA from Columbia Business School with a concentration in corporate finance in 2005.
SCIENTIFIC ADVISORY COUNSEL
Joseph Bonventre, MD, CHAIR
Brigham and Womens, Harvard University
Michael Koren, MD
First Coast Heart and Vascula
Anupam Agarwal, MD
University of Alabama - Birmingham
Sumit Mohan, MD
Jack Boyd, MD
Ken Newell, MD
Matthew Cooper, MD
Matthew Weir, MD
University of Maryland